Amendment: Chief Executive Officer Moulder Leon O Jr converted options into 693,175 shares, increasing direct ownership by 3,465% to 161,155 units (SEC Form 4)

9/17/24 8:54:38 PM ET

$ZBIO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZBIO alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get started Learn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds: Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters: Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk: Multitask with confidence and let Quantsinow read breaking news out loud.

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts: Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications: Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks: Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts: Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get started Learn more

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

Live feeds
Audio squawk
Compact mode in feeds
Email alerts
App push alerts
Unlimited insights reads
Unlimited subscriptions
Advanced filters in live feeds
Support
No ads
AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time

5 million+

Real-time news alerts sent out to Quantisnow users

700,000+

Latency of news delivery pipelines to users via mobile app, webhooks, and email

<100ms

Get the next $ZBIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZBIO

Date	Price Target	Rating	Analyst
3/20/2025	$35.00	Outperform	Wedbush
2/4/2025	$19.00	Outperform	Wolfe Research
12/16/2024	$30.00	Buy	H.C. Wainwright
11/5/2024	$34.00	Buy	Rodman & Renshaw
10/8/2024	$45.00	Buy	Guggenheim
10/8/2024	$40.00	Overweight	Morgan Stanley
10/8/2024	$35.00	Buy	Jefferies
10/8/2024	$27.00	Buy	Citigroup

More analyst ratings

$ZBIO
Press Releases

Fastest customizable press release news feed in the world

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
3/17/25 7:05:00 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab - WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmac
2/5/25 7:05:00 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutica
1/28/25 8:00:00 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wedbush initiated coverage on Zenas Biopharma with a new price target
Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00
3/20/25 8:00:59 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research initiated coverage on Zenas Biopharma with a new price target
Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00
2/4/25 7:13:29 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target
H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00
12/16/24 6:47:20 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
2/19/25 4:01:11 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
2/11/25 4:20:30 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Chief Executive Officer Moulder Leon O Jr bought $718,100 worth of shares (70,000 units at $10.26), increasing direct ownership by 41% to 241,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
12/4/24 9:03:46 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Von Moltke Lisa
3 - Zenas BioPharma, Inc. (0001953926) (Issuer)
3/21/25 4:01:08 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
2/19/25 4:01:11 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
2/11/25 4:20:30 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
SEC Filings

SEC Form SCHEDULE 13G filed by Zenas BioPharma Inc.
SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
4/1/25 9:47:58 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form S-8 filed by Zenas BioPharma Inc.
S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)
3/11/25 6:51:25 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 10-K filed by Zenas BioPharma Inc.
10-K - Zenas BioPharma, Inc. (0001953926) (Filer)
3/11/25 6:15:29 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
Leadership Updates

Live Leadership Updates

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
3/17/25 7:05:00 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

$ZBIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
11/12/24 10:40:28 AM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
10/21/24 4:18:16 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
9/25/24 6:00:11 PM ET
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care

Amendment: Chief Executive Officer Moulder Leon O Jr converted options into 693,175 shares, increasing direct ownership by 3,465% to 161,155 units (SEC Form 4)

Weekly insight reads limit reached.

Meet Quantisnow

Invest smarter

Save time

Get alerted immediately

Elevate your trading.Start using Quantisnow today.

Simple no-tricks pricing

Quantisnow Plus

What's included

Chat with this insight

Recent Analyst Ratings for $ZBIO

$ZBIO Press Releases

Fastest customizable press release news feed in the world

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

$ZBIO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wedbush initiated coverage on Zenas Biopharma with a new price target

Wolfe Research initiated coverage on Zenas Biopharma with a new price target

H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

$ZBIO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

Chief Executive Officer Moulder Leon O Jr bought $718,100 worth of shares (70,000 units at $10.26), increasing direct ownership by 41% to 241,155 units (SEC Form 4)

$ZBIO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Von Moltke Lisa

Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

$ZBIO SEC Filings

SEC Form SCHEDULE 13G filed by Zenas BioPharma Inc.

SEC Form S-8 filed by Zenas BioPharma Inc.

SEC Form 10-K filed by Zenas BioPharma Inc.

$ZBIO Leadership Updates

Live Leadership Updates

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

$ZBIO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Zenas BioPharma Inc.

SEC Form SC 13G filed by Zenas BioPharma Inc.

SEC Form SC 13G filed by Zenas BioPharma Inc.

Elevate your trading.
Start using Quantisnow today.

Recent Analyst Ratings for
$ZBIO

$ZBIO
Press Releases

$ZBIO
Analyst Ratings

$ZBIO
Insider Purchases

$ZBIO
Insider Trading

$ZBIO
SEC Filings

$ZBIO
Leadership Updates

$ZBIO
Large Ownership Changes